Michael D. Abramowitz

The Antiemetic Effect of Droperidol Following Outpatient Strabismus Surgery in Children

The Antiemetic Effect of Droperidol Following Outpatient Strabismus Surgery in Children Michael Abramowitz;Tae Oh;Burton Epstein;Urs Ruttimann;David Friendly; Anesthesiology

Antiemetic Effectiveness of Intraoperatively Administered Droperidol in Pediatric Strabismus Outpatient Surgery - Preliminary Report of a Controlled Study

Low doses (0.05 mg/kg) of intravenously administered droperidol were given intraoperatively to randomly assigned pediatric strabismus patients in a controlled double-masked paradigm. No difference between control and treatment groups in the severity of vomiting was noted in the postanesthesia recovery room, but such a difference was probably present in the hospital rooms during the interval between room arrival and the meeting of hospital discharge criteria. Administration of the drug did not appear to produce somnolence sufficient to delay postoperative recovery.

Rectal metho-hexitone induction in pediatric outpatients: Physostigmine does not enhance recovery

Rectal methohexitone (25 mg·kg-1) was used to induce anaesthesia in 15 unpremedicated children scheduled to undergo bilateral myringotomies as outpatients. Induction time ranged from 4 to 11 minutes. In the recovery room, all children received a slow intravenous injection of physostigmine (60 μg·kg-1), or saline in a double blind randomized fashion. The use of physostigmine did not significantly decrease the recovery room stay as compared to placebo (34 vs. 43 minutes). Vomiting and soiling were two side-effects associated with the use of physostigmine.RéuméLe méthohexitone (25 mg·kg-1 @#@) par voie rectale a été utilisé afin d’induire l’anesthesie chei 15 enfants non-prémédiqués, cédulés pour myringotomies bilatérales en externe. Le temps d’induction s’étend de 4 à 11 minutes. Dans la salle de réveil, tous les enfants ont reçu une injection intraveineuse lente de physostigmine (60 μg·kg-1 @#@), ou de solution physiologique à double insu et d’une façon randomisee. L’utilisation de la physostigmine n’a pas diminué significativement le temps de séjour en salle de réveil comparativement au placebo (34 vs 43 minutes). Les vomissements et le salissement des couches étaient deux effets secondaires associés a l’usage de la physostigmine.